Adiposs is a Swiss medtech start-up company, a spin-off of University of Geneva, developing medical imaging products and technologies. The company is developing breakthrough technology for non-invasive detection of brown fat. Adiposs will make ImageBAT an essential diagnostic product in cancer management. It will transform cachexia from undetectable into a preventable syndrome of cancer giving patients improved and longer lives.
ADVITOS is an ISO 13485 certified company with a CE-marked multi organ support device and with 55 employees covering all aspects necessary for developing and marketing medical devices.
ADVOS (ADVanced Multi Organ Support) is the world’s first and only device that enables holistic treatment of multiple organ failure through combined removal of water-soluble (kidney), protein-bound toxins (liver and kidney), CO2 (lung) and correction of acid-base disbalances in acidosis.
AorticLab was founded by experienced MedTech professionals and physicians with the aim to develop new technologies for the cardiovascular procedures and provide the bio-technological advancement. AorticLab program is based on the development of two devices for the care of the untreated stenotic valve and increasing the safety and the effectiveness of the TAVI procedures.
ARTIDIS AG is a spinoff from the Biozentrum, University of Basel, Switzerland that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. ARTIDIS nanotechnology platform integrates different types of clinical data into the ARTIDISNet digital platform, allowing physicians to significantly shorten the current diagnostic process and bringing benefit to both the patient and the healthcare system. ARTIDIS enables professionals to design personalized cancer treatment plans tailored to the individual patient needs and desired outcomes. https://artidis.com/
Bayoomed medical software
BAYOOMED is your partner for the engineering of medical apps and medical software. With more than 250 person years of project experience, BAYOOMED is highly professional in the regulated CE & FDA environment. We support more than 800 medical and pharma companies and are among the most experienced medical software developers in Europe.
We engineer MHEALTH / EHEALTH applications under iOS (iPhone & iPad) and Android according to IEC 62304 and support product developers and innovators from the pharmaceutical and medical technology sectors in all phases of software product lifecycle. Our Quality management processes certified by TÜV Hessen according to ISO 13485 are a testament to our passion for sustainable solutions and distinct customer focus.
DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the biopharmaceutical and chemical domains.
We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.
DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.
Dynamic Light is developing a technology for non-invasive, continuous, and quantitative visualization of blood flow, vascularity, and perfusion during surgery. We achieve this real time imaging using patented algorithms and software that can work on a wide variety of platforms already in place in hospital operating rooms. In most cases, little or no hardware modification will be required to add speckle capabilities to existing surgical imaging systems, making it an economical, value-adding upgrade for hospital administrators. Importantly, speckle imaging also integrates seamlessly into existing surgical workflows, making it easy for surgeons to adopt the technology. Once in use, the technical superiority of speckle imaging will make it a ‘need to have’ capability in the operating room.
MagForce AG is a publicly traded German company based in Berlin, Germany that develops medical devices that generate magnetic hyperthermia to treat cancer. The company was founded in 1997 as a spin-off from Charité.
MagForce has developed a solution of iron oxide nanoparticles that is directly injected into the tumor. A couple of days later, the person with the tumor is placed inside a large piece of equipment similar to an MRI machine, also manufactured by MagForce, which creates a strong, fast-changing magnetic field. The changing magnetic field causes the particles to vibrate, which in turn generates heat, destroying the tissue, or at least making the tumor more vulnerable to other treatments, like radiation. Generally there are six such sessions in the machine.
The company was listed on the Frankfurt exchange in 2007, and received the CE mark for its system in 2010.
MedCu Technologies is the world’s first and only provider of wound dressing products that impregnated with copper particles that received the CE Certification and FDA clearance for marketing. This patent-protected pioneering implementation of copper properties, results in an innovative antimicrobial dressing product that provides a barrier for microbial introduction and support wound healing, while concurrently act as a superior antimicrobial. The company holds ISO 13485. Offered at an attractive cost-effective price the copper-based dressings are ideal for acute, critical and chronic wounds. The estimated advance wound care dressing potential market is estimated 2-4 billion USD.
The company entering the commercialization phase and development of third generation of copper advanced wound healing.
MedCu is planing to initiate a fund raising round during the second half of 2020.
MedTrix Healthcare aims to be a leading navigator of the paradigm shifts occurring in the pharmaceutical industry. Ongoing trends show that both patients and healthcare professionals are increasingly moving online to manage health outcomes. Simultaneously, pharmaceutical companies are establishing across-the-board virtual ecosystems, on digital platforms, to create seamless interactions with all the stakeholders.
The Global Pharmaceutical Industry is at an inﬂection point, where it is pivoting from ‘doing Digital’ to ‘being Digital’. As the industry leaders re-invent their marketing programs we, at MedTrix, have readied ourselves to be eager and able partners in this evolution. We have the know-how to fulﬁl the technical and scientiﬁc requirements for this progression. At MedTrix we combine science, technology and strategy with our ISO certiﬁed systems and processes to accomplish speciﬁc business objectives.
Novigenix is a diagnostics company that has developed a novel immuno-transcriptomics platform to leverage the mRNA signatures of immune cells to detect cancer. The company has established a database of over 1,500 patients at risk of colorectal cancer (CRC) and has launched its first blood based molecular diagnostic product, Colox, for the early detection of colon cancer. The Colox test is currently on the market in Switzerland and has a CE mark in the EU.
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. The Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
Preci Health is a spin-off of Preciflex SA, a world leader in micro-fluidic technology that is implemented in various technologies like in case of Hydro precision watches (HYT watches)
Foundation year – 09/2017 HQ – Neuchatel, Switzerland
In collaboration with Midatech's experts, Preci Health's teams are also developing a unique chemical and pharmaceutical know-how to concentrate drugs while maintaining the prescribed doses (viscosity control, etc.).
PreciPoint is addressing the issue of cancer diagnostics by providing a scalable and reliable system for the digitalization of microscopic samples which is tolerant against inconsistencies in tissue preparation with an innovative, smartphone-like interface to prevent extensive training requirements. The company is offering a fully integrable platform together with the digitalization system including online and cloud storage solutions, control-, viewer- and image manipulation-software as well as extensive interfaces for the integration of third-party software to include additional functionalities. This combination will lead to a significant improvement in quality and efficiency of pathological diagnoses and will contribute to take pathology to the age of digitalization while significantly improving diagnostic quality and patient care.
PreciPoint offers a variety of integrated hardware and software products. The design of the, the company’s core product, the digital microscopy platform M8 started from scratch, consequently following the path of digitalization during the six-year development period, resulting in a solution that offers superior design and functionality compared to classical digital microscopes, which in most cases are just analogues microscopes with a camera and a motorized stage attached. The capabilities of PreciPoint to scale its solutions is well developed as software products are inheritably scalable and the production of the hardware can be extended at any point in time.
Additional value is created by the integration capacity of all our products, allowing the seamless incorporation of third-party applications as well as by the unmatched capability to tolerate inconsistencies in the sample preparation and being able to generate high-quality images even from most difficult specimen. This offers the possibility to run digital analyses on basically every sample opening the gate for new diagnostic tools to a large segment of patients.
Pulsify Medical develops ultrasound patches for continuous, non-invasive, real-time monitoring of patients' cardiac performance, in particular cardiac output. The Pulsify patch is wearable, flexible & smart and monitors hospital ICU patients, patients in the hospital ward and patients at home. Pulsify Medical is a spin-off of imec and KU Leuven (Belgium) and builds on the unique and IP-protected technology of these renowned research institutes.
Our mission is to improve the success of surgeries by enabling surgeons better to distinguish different tissue types and identify malignant lesions. Our proprietarytechnology enables multiparametric endoscopy where various structural and functional images are provided simultaneously.
The first application of ourreal-time multispectral imaging technology is in transurethral resections of bladder tumor (TURBT), where we expect it will contribute to reducing disease recurrence and minimizing collateral tissue damage.
The proprietary Univfy AI Platform makes it easy for women and couples to access the most effective and safest fertility treatment. It is the only highly scalable AI platform that provides scientifically validated, personalized reports that counsel patients from diverse demographics about their probability of having a baby with IVF. Univfy improves the experience for patients and efficiency for providers.